Furiex Pharmaceuticals Inc  

(Public, NASDAQ:FURX)   Watch this stock  
Find more results for FURX
- Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -5.05
Shares 10.82M
Beta     -
Inst. own 57%

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -203.22% -41.79%
Operating margin -177.81% -34.42%
EBITD margin - -34.34%
Return on average assets -62.11% -32.39%
Return on average equity -359.25% -105.90%
Employees 24 -
CDP Score - -


3900 Paramount Pkwy Ste 150
MORRISVILLE, NC 27560-5401
United States - Map
+1-919-4567800 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Furiex Pharmaceuticals, Inc. is a drug development collaboration company. The Company�s product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas. Its programs include Priligy, Alogliptin Nesina, Alogliptin/Actose Combination, Alogliptin/Metformin Combination, Fluoroquinolone, Mu Delta and PPD 10558. In November 2011, it acquired full exclusive license rights to develop and commercialize the compound MuDelta under its existing development and license agreement with Janssen Pharmaceutica N.V. Effective July 2, 2014 Forest Laboratories Inc, a unit of Actavis PLC, acquired the entire share capital of Furiex Pharmaceuticals Inc.